| The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. | |
| | |
MedLine Citation:
|
PMID: 18048383 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The use of adjuvant carboplatin in the management of stage I seminoma of the testis has been limited by the lack of long-term data. In this study, we address this issue for the first time. PATIENTS AND METHODS: Data on 199 patients treated with single-agent carboplatin for stage I seminoma of the testis were prospectively collected. Overall mortality, deaths from circulatory disease and the incidence of second cancers were compared with expected values derived from the UK general population. RESULTS: The median follow-up for the cohort was 9.0 years (range 0.1-20.1). There has been no excess in overall mortality [standardised mortality ratio (SMR) 0.89; 95% CI 0.36-1.83], death from circulatory diseases (SMR 1.44; 95% CI 0.39-3.69) or the incidence of second nontestis cancers (standardised incidence ratio 0.96; 95% CI 0.26-2.45) in this group of patients. These findings also applied to specific follow-up periods of >5 or 10 years. Specifically, neither haematological nor solid nontestis tumours occurred in excess. There was an increase in the long-term development of contralateral testis cancers. CONCLUSIONS: This study addresses some of the concerns surrounding the long-term safety of single-agent carboplatin. It also helps in planning long-term follow-up for patients receiving this form of treatment. |
| | |
Authors:
|
T Powles; D Robinson; J Shamash; H Moller; N Tranter; T Oliver |
Related Documents
:
|
22740443 - How i treat immune thrombocytopenia (itp): the choice between splenectomy or a medical ... 20388763 - Nursing home-acquired pneumonia: a 10 year single-centre experience. 2157983 - A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibr... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2007-11-28 |
Journal Detail:
|
Title: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Volume: 19 ISSN: 1569-8041 ISO Abbreviation: Ann. Oncol. Publication Date: 2008 Mar |
Date Detail:
|
Created Date: 2008-02-28 Completed Date: 2008-03-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9007735 Medline TA: Ann Oncol Country: England |
Other Details:
|
Languages: eng Pagination: 443-7 Citation Subset: IM |
Affiliation:
|
Department of Medical Oncology, St Bartholomew's Hospital, London, UK. thomas.powles@bartsandthelondon.nhs.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Agents / therapeutic use Carboplatin / therapeutic use* Carcinoma, Small Cell / epidemiology Cause of Death Chemotherapy, Adjuvant Cohort Studies Follow-Up Studies Great Britain / epidemiology Hematologic Neoplasms / epidemiology Hodgkin Disease / epidemiology Humans Incidence Lung Neoplasms / epidemiology Lymphatic Metastasis Male Meningeal Neoplasms / epidemiology Meningioma / epidemiology Middle Aged Neoplasm Staging Neoplasms, Second Primary / epidemiology* Seminoma / drug therapy*, mortality*, pathology, secondary Survival Analysis Testicular Neoplasms / drug therapy*, mortality, pathology Treatment Outcome Tumor Markers, Biological / analysis |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Tumor Markers, Biological; 41575-94-4/Carboplatin |
| Comments/Corrections | |
Comment In:
|
Ann Oncol. 2008 Mar;19(3):407-8
[PMID:
18227108
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma.
Next Document: Resveratrol-induced apoptosis depends on the lipid kinase activity of Vps34 and on the formation of ...